| A non–D2-receptor-binding drug for the treatment of schizophrenia KS Koblan, J Kent, SC Hopkins, JH Krystal, H Cheng, R Goldman, ... New England Journal of Medicine 382 (16), 1497-1506, 2020 | 257 | 2020 |
| Dynamic measurement of myosin light-chain-domain tilt and twist in muscle contraction JET Corrie, BD Brandmeier, RE Ferguson, DR Trentham, ... Nature 400 (6743), 425-430, 1999 | 247 | 1999 |
| SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action N Dedic, PG Jones, SC Hopkins, R Lew, L Shao, JE Campbell, KL Spear, ... Journal of Pharmacology and Experimental Therapeutics 371 (1), 1-14, 2019 | 152 | 2019 |
| Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm CH Vinkers, MJV van Bogaert, M Klanker, SM Korte, R Oosting, ... European journal of pharmacology 585 (2-3), 407-425, 2008 | 126 | 2008 |
| Inhibitors of kinesin activity from structure-based computer screening SC Hopkins, RD Vale, ID Kuntz Biochemistry 39 (10), 2805-2814, 2000 | 120 | 2000 |
| Fluorescence polarization transients from rhodamine isomers on the myosin regulatory light chain in skeletal muscle fibers SC Hopkins, C Sabido-David, JET Corrie, M Irving, YE Goldman Biophysical journal 74 (6), 3093-3110, 1998 | 107 | 1998 |
| Orientation changes of the myosin light chain domain during filament sliding in active and rigor muscle SC Hopkins, C Sabido-David, UA Van Der Heide, RE Ferguson, ... Journal of molecular biology 318 (5), 1275-1291, 2002 | 98 | 2002 |
| Model-independent analysis of the orientation of fluorescent probes with restricted mobility in muscle fibers RE Dale, SC Hopkins, UA an der Heide, T Marszałek, M Irving, ... Biophysical journal 76 (3), 1606-1618, 1999 | 78* | 1999 |
| Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine M Kokkinou, EE Irvine, DR Bonsall, S Natesan, LA Wells, M Smith, ... Molecular psychiatry 26 (6), 2562-2576, 2021 | 74 | 2021 |
| Orientation changes of fluorescent probes at five sites on the myosin regulatory light chain during contraction of single skeletal muscle fibres C Sabido-David, SC Hopkins, LD Saraswat, S Lowey, YE Goldman, ... Journal of molecular biology 279 (2), 387-402, 1998 | 57 | 1998 |
| Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults KS Koblan, SC Hopkins, K Sarma, F Jin, R Goldman, SH Kollins, A Loebel Neuropsychopharmacology 40 (12), 2745-2752, 2015 | 56 | 2015 |
| Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress CH Vinkers, M Klanker, L Groenink, SM Korte, JM Cook, ML Van Linn, ... Psychopharmacology 204, 299-311, 2009 | 51 | 2009 |
| Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study CU Correll, KS Koblan, SC Hopkins, Y Li, H Dworak, R Goldman, ... npj Schizophrenia 7 (1), 63, 2021 | 49 | 2021 |
| Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia MLR Heffernan, LW Herman, S Brown, PG Jones, L Shao, MC Hewitt, ... ACS medicinal chemistry letters 13 (1), 92-98, 2021 | 44 | 2021 |
| Electric field and conformational effects of cytochrome c and solvent on cytochrome c peroxidase studied by high-resolution fluorescence spectroscopy H Anni, JM Vanderkooi, KA Sharp, T Yonetani, SC Hopkins, L Herenyi, ... Biochemistry 33 (12), 3475-3486, 1994 | 40 | 1994 |
| Benzo [d] isoxazol-3-ol DAAO inhibitors QK Fang, S Hopkins, M Heffernan, M Chytil, P Wipf US Patent 7,166,725, 2007 | 37 | 2007 |
| Structural, Kinetic, and Pharmacodynamic Mechanisms of d-Amino Acid Oxidase Inhibition by Small Molecules SC Hopkins, MLR Heffernan, LD Saraswat, CA Bowen, L Melnick, ... Journal of medicinal chemistry 56 (9), 3710-3724, 2013 | 36 | 2013 |
| Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans SC Hopkins, N Dedic, KS Koblan Translational Psychiatry 11 (1), 228, 2021 | 35 | 2021 |
| Pyrrole and pyrazole DAAO inhibitors QK Fang, S Hopkins, M Heffernan, M Chytil US Patent 7,488,747, 2009 | 35 | 2009 |
| Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with … SC Hopkins, A Ogirala, A Loebel, KS Koblan Schizophrenia bulletin 44 (3), 593-602, 2018 | 33 | 2018 |
Kenneth KoblanSunovion PharmaceuticalsVerified email at sunovion.com
